eribulin

Eribulin (B1939) is a nonpaclitaxel microtubule kinetic inhibitor with anticancer activity that inhibits polymerization of microtubule protein subunits by preventing lengthening and shortening of microtubules during cell division.Eribulin is used in the study of metastatic breast cancer and solid tumors.

Mal-PEG2-VCP-Eribulin is a chemotherapeutic compound comprising an antibody-drug conjugate (ADC) linker (Mal-PEG2-VCP) and the microtubule inhibitor Eribulin[1]. This compound uniquely targets microtubules, offering a novel approach to cancer treatment. Eribulin is specifically utilized in creating targeted Eribulin-based drugs for antibody conjugates[1].

VCP-Eribulin, an Eribulin-based drug for antibody conjugates[1], combines the VCP (ADCs linker) with Eribulin, a distinct microtubule inhibitor used in cancer treatments[2].

Mal-(CH2)5-Val-Cit-PAB-Eribulin is a potent antitumor ADC drug-linker conjugate utilizing Eribulin, an anti-microtubule agent, connected through the Mal-(CH2)5-Val-Cit-PAB linker.

Eribulin mesylate (E7389 mesylate) belongs to natural product derivatives and is a microtubule-targeted anticancer agent, functioning as a microtubule dynamics inhibitor that suppresses tubulin polymerization through tubulin binding, with cell permeability. This drug is used for the treatment of metastatic breast cancer.

VcMMAE-Eribulin is a (Drug-Linker Conjugates for ADC) composed of the linker and cytotoxic molecules MMAE and Eribulin. This conjugate is used in the synthesis of ADCs.

Deruxtecan-Eribulin is a Drug-Linker Conjugate for ADC comprised of a linker and two cytotoxic molecules: Exatecan (a DNA topoisomerase I inhibitor) and Eribulin (a microtubule inhibitor). This compound is utilized in the synthesis of ADCs.

Mal-PEG2-Val-Arg-PABC-OMe-Eribulin (Compound L-1) is a drug-linker conjugate composed of O-Me Eribulin and the linker Mal-PEG2-Val-Cit-PAB-OH. It is utilized in the synthesis of anti-HER3/MET antibody-drug conjugates (ADC).

Eribulin-GGFG (Compound GGFG) is a drug-linker conjugate for antibody-drug conjugates (ADCs). Comprised of the cytotoxic agent exatecan and a connecting linker, it facilitates the synthesis of ADCs [1].

Fmoc-PEG6-VCP-Eribulin is a derivative of Eribulin. Eribulin (E7389) is an anticancer agent targeting microtubules (microtubule) and is utilized in the study of metastatic breast cancer. It inhibits cancer cell proliferation by binding to tubulin and microtubules.

Eribulin-D3 mesylate is the deuterated form of Eribulin mesylate (T13687-GMP). Eribulin mesylate, an anti-cancer agent that targets microtubules (microtubule), is utilized for cancer research.

Farletuzumab ecteribulin is an antibody-drug conjugate (ADC) consisting of the humanized antibody farletuzumab, which targets the folate receptor alpha (FRA), with an antibody-to-drug ratio of 4.0. In vitro, farletuzumab ecteribulin exhibits cytotoxic and antitumor activity against FRA-positive cells.